fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Fed Leaves Rates Near Zero Fueling Market Records! – $AAPL $ATOS $FATE $INM $INMB $IRNT $TSLA $XBI Rise!

By John F. Heerdink, Jr.
“Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright, American Architect, June 8, 1867 – April 9, 1959


Happy Hump Day!

For the 3rd consecutive day this week, the markets powered upward & every index ended in record territory. Today’s move seemed to be further fueled by the Fed’s decision to keep interest rates near zero, while also committing to taper net asset purchases by $15B this month; moves that were somewhat expected.  The Fed also reemphasized that in order for rates to be raised, we would need to reach maximum employment. They also restated and assured investors that the current inflation pressures are truly transitory at best. In turn, 8 of the 11 sectors closed in positive territory, while the S&P 500 closed at 4,660.57 (+.37%), the Dow 30 closed at 36,157.58 (+.29%), & the Nasdaq also closed at 15,811.58 (+1.04%). The small caps on the Russell 2000 also closed significantly higher at 2,404.28 (+1.8%) & the MicroCaps jumped impressively as the iShares Micro-Cap ETF (IWC) closed at $154.56, (+2.08%).

The macroeconomic schedule was also quite busy today and provided some better than expected reports. The ISM Non-Manufacturing Index report for October confirmed a rise to 66.7%, while the factory orders for manufactured goods report confirmed a rise by .2% M/M in September. The ADP Employment Change report approximated that 571k jobs were added to private-sector payrolls in October. The IHS Markit Services PMI report confirmed a rise to 58.7 in the final reading for October. The weekly MBA Mortgage Applications Index report confirmed drop by 3.3%. The weekly crude oil inventories was confirmed to have risen by 3.29M barrels (a rise for a second consecutive weeks), while oil prices fell 3.6% to close at $80.81/bbl. Tomorrow’s schedule will provide the weekly Initial and Continuing Claims report, the preliminary Productivity and Unit Labor Costs report for Q3, & the Trade Balance for September. 

The yield curve bounced back as the 2-yr yield rose 2 basis points to .47%, & the 10-yr yield rose 3 basis points to 1.58%. The U.S. Dollar Index moved lower by .2% to 93.90.

GOLD/SILVER  

The precious metals markets ended with gold prices closing at $1,772, -$17/oz. and silver closed at $23.58, +$.02/oz.  Hecla Mining Company (HL) closed at $5.89, +.34%.

BIOTECH $XBI CONTINUE

The SPDR S&P Biotech ETF (XBI) closed at $134.15, +2.20% (~+6.7% this week), the iShares Nasdaq Biotechnology ETF (IBB) closed at $164.78, +1.30%, & the NYSE ARCA Biotech Index (^BTK) closed at $5,815.27, +1.04%.

On October 23, Dr. Steven Quay CEO of Atossa Therapeutics (NASDAQ: ATOS) published an interesting and informative video called “Long COVID Is An important Issue.” You may view by clicking here now.

Today, after the close, INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported its financial results for the third quarter ended September 30, 2021 and provided a business update including the announcing of a second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) & Cash and cash equivalents of $84.5 million on September 30th. RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “In the first patient treated in our Phase I study of INKmune™ in high-risk myelodysplastic syndrome, INKmune™ was found to safely produce cancer killing memory-like NK cells while increasing proliferation and persistence of those NK cells. As expected, the memory-like NK cells generated in vivo killed NK-resistant cancer cells in vitro. We now have data from Day 73 post first treatment and over 60% of his peripheral blood NK cells remained activated and highly functional in vitro. We are continuing to screen patients for future enrollment and are in the process of expanding the number of clinical trial sites in the UK and overseas. Our latest drug stability data allows us to extend the shelf-life to over 12 months and consequently we initiated a manufacturing scale up to secure drug supplies as the program expands. In our Phase I trial of XPro in AD, we have shown that XPro decreases biomarkers of neuroinflammation and neurodegeneration while improving biomarkers of CNS repair. We hope to demonstrate these effects on cognition in the Phase II mild AD trial that is on track to initiate later this year.” Shares of  INmune Bio (NASDAQ: INMB) closed at $19.53, +.72%, after reaching an intraday high of $20.

 

I recently hosted a FREE Tribe Public Presentation and Q&A event with INMB’s CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss, who delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video that has been viewed over 21k times now to learn more. 


Today, InMed Pharmaceuticals (INM) announced that it has filed an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others. Dr. Eric Hsu, Senior Vice President Pre-Clinical Research & Development at InMed stated, “We are very encouraged by this initial data demonstrating potential for the use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs. Expanding our patent portfolio to include, in addition to cannabinol (CBN), an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications demonstrates our continued commitment to our pharmaceutical programs and the potential of rare cannabinoids in medicine.”

TECH – EV

Amazon.com, Inc. (NASDAQ: AMZN, $3,374, +2.15%). Click here to see the details of their Q3 miss that was reported last week.

Shares of Apple (AAPL) closed at $151.49, +.98%. On Oct. 28th Apple® announced financial results for its fiscal 2021 fourth quarter ended September 25, 2021 and reportedly falling short of Wall Street’s expectations. The Company posted a September quarter revenue record of $83.4 billion, up 29 percent year over year, and quarterly earnings per diluted share of $1.24. Tim Cook, Apple’s CEO stated, “This year we launched our most powerful products ever, from M1-powered Macs to an iPhone 13 lineup that is setting a new standard for performance and empowering our customers to create and connect in new ways. We are infusing our values into everything we make — moving closer to our 2030 goal of being carbon neutral up and down our supply chain and across the lifecycle of our products, and ever advancing our mission to build a more equitable future.” Luca Maestri, Apple’s CFO stated, “Our record September quarter results capped off a remarkable fiscal year of strong double-digit growth, during which we set new revenue records in all of our geographic segments and product categories in spite of continued uncertainty in the macro environment. The combination of our record sales performance, unmatched customer loyalty, and strength of our ecosystem drove our active installed base of devices to a new all-time high. During the September quarter, we returned over $24 billion to our shareholders, as we continue to make progress toward our goal of reaching a net cash neutral position over time.” Apple’s board of directors has declared a cash dividend of $0.22 per share of the Company’s common stock. The dividend is payable on November 11, 2021 to shareholders of record as of the close of business on November 8, 2021.

Shares of Microsoft Corp. (MSFT) closed at $334, +.26% after last week’s release of their Q1 2022 fiscal earnings report. Here are a few of the numbers from the report: Revenue: $45.3 billion versus $43.93 billion expected, Earnings per share: $2.71 versus $2.07 expected, Intelligent Cloud: $16.98 versus $16.58 billion expected, & Productivity & Business processes: $15.04 versus $14.70 billion expected. Satya Nadella, chairman and chief executive officer of Microsoft stated, “Digital technology is a deflationary force in an inflationary economy. Businesses – small and large – can improve productivity and the affordability of their products and services by building tech intensity. The Microsoft Cloud delivers the end-to-end platforms and tools organizations need to navigate this time of transition and change.”

VP Watchlist company Tesla (TSLA) closed $1,213.86, +3.57% & is valued at $1.18T. On Oct 25, Hertz’ (HTZZ, $27.01, -1.06%) announced that they are making a significant investment to offer the largest EV rental fleet in North America and one of the largest in the world, which includes an initial order of 100,000 Tesla’s (+$4B investment) by the end of 2022 and new EV charging infrastructure across the company’s global operations. Last week, Tesla also released its financial results for the third quarter of 2021 they topped estimates but this win was a surprise. Tesla’s revenues came in at $13.76 billion vs. $13.91 billion expected, $8.77 billion Y/Y & Adjusted earnings per share came in at $1.86 vs. $1.67 expected, 76 cents Y/Y. Tesla also reconfirmed the company’s guidance that it will achieve 50% average annual growth in vehicle deliveries over a stated multi-year horizon. Today, Elon Musk apparently stated that there is no signed contract with Heartland that it would not have any economic impact. 

Shares of Lucid Group (LCID) closed at $36.55, +4.03%. Lucid will host a conference call to discuss its third quarter 2021 results on Monday, November 15, 2021 at 2:00 pm PT / 5:00 pm ET. The company will issue an earnings press release with the dial-in number and a link to the live webcast on its investor relations website at ir.lucidmotors.com prior to the conference call. Lucid’s mission is to inspire the adoption of sustainable energy by creating the most captivating electric vehicles, centered around the human experience. The company’s first car, Lucid Air, is a state-of-the-art luxury sedan with a California-inspired design underpinned by race-proven technology. Lucid Air features a luxurious full-size interior space in a mid-size exterior footprint. Customer deliveries of Lucid Air, which is produced at Lucid’s new factory in Casa Grande, Arizona, will begin on October 30, 2021.

Shares of IronNet, Inc. (IRNT), an innovative leader transforming cybersecurity through Collective Defense, closed at $12.22, +1.83. Last week, IronNet announced that it has joined the Microsoft Intelligent Security Association (MISA), a nomination-only association, demonstrating IronNet’s long-term commitment with Microsoft to deliver better security solutions to customers. As a Microsoft partner, IronNet, through its innovative Collective Defense platform, empowers Microsoft customers to execute safe and seamless migrations to the cloud amidst the increasing volume of highly-aggressive and sophisticated cyberattacks. IronNet Founder and Co-CEO, General (Ret.) Keith Alexander, “As we continue to see an increase in malicious cyberattacks against both the public and private sectors, we are pleased to join the Microsoft Intelligent Security Association to advance how we defend together. MISA’s mission directly aligns with our mission at IronNet: to develop integrated and innovative ways to better defend together against an evolving cyber threat landscape.”  

DISNEY

Another VP Watchlist company, Walt Disney (DIS), closed $170.08, +.15%. Disney is reportedly planning to raise ticket prices for Disneyland will likely drive revenue forward. Surprise! Surprise! There is also a good chance that they will continue to do so across their entertainment platform as we move forward too. Disney will discuss fiscal full year and fourth quarter 2021 financial results via a live audio webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 10, 2021. Results will be released after the close of regular trading on November 10, 2021. To listen to the webcast, please visit www.disney.com/investors.

MCD 

Shares of McDonald’s (MCD) closed at $250.40, +.47% after last week’s release of their Q3 results. McDonald’s President and Chief Executive Officer, Chris Kempczinski stated, “Our third quarter results are a testament to our unparalleled scale and agility. Our global comparable sales increased 10% over 2019, which was delivered across an omnichannel experience that is focused on meeting the needs of our customers. We continue to execute our strategic growth plan and run great restaurants so that we can drive long-term, sustainable growth for all of our stakeholders.” Global comparable sales were up 12.7% in the third quarter and increased 10.2% on a 2-year basis & Year-to-date digital Systemwide sales* were about $13 billion, or over 20% of total Systemwide sales in our top six markets.

FORD

Shares of Ford (F) closed at $18.63, +3.44%. On Oct, 27, Ford Motor Company (F) reported its 2021 third quarter financial results after the markets closed. Ford generated quarterly revenue of $35.7 billion, net income of $1.8 billion, adjusted EBIT of $3.0 billion; North America auto EBIT margin of 10.1%/. Ford increased guidance for full-year 2021 adjusted EBIT to between $10.5 billion and $11.5 billion & expects cash flow over current planning period to be more than sufficient to fund growth priorities; announces resumption of regular stock dividend in fourth quarter.

MEMES WATCH

AMC Entertainment (AMC) closed at $40.79, +5.16%. Yesterday, after the close AMC Theaters (NYSE:AMC), the largest theatrical exhibitor in the United States, in Europe & the Middle East and in the world, announced that it is again rewarding its self-identified shareholders through AMC Investor Connect. Existing and new participants who sign up by year-end in AMC Investor Connect will be encouraged to come to AMC movie theatres in the United States in November, December, or January with the offer of another Free Large Popcorn, useable with the purchase of a ticket. This is the second time AMC has made such an offer to its shareholders. The first such time started in June of 2021, with that free large popcorn offer valid through yesterday October 31.

Bed Bath & Beyond Inc. (NASDAQ: BBBY) announced yesterday that it expects to complete its $1 billion three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule. Shares of BBBY closed at $19.30, +15.22% . 

GameStop (GME) closed at $218.33, +5.48%. According to Yahoo finance Brian Cheung, the Securities and Exchange Commission released a 45-page report recently offering no specific policy recommendations following the early 2021 frenzy over GameStop (GME) stock.

Shares of Seanergy Maritime Holdings Corp. (SHIP) closed at $1.10, +1.85% after recently announcing its financial results for the third quarter ended September 30, 2021. Highlights of the Third Quarter of 2021: Gross revenues: $50 million in Q3 2021, as compared to $20.4 million in Q3 2020, up 146%, Net Income: $20.1 million in Q3 2021, as compared to $3.6 million in Q3 2020, up 459%, EBITDA1: $30.1 million in Q3 2021, as compared to $12.7 million in Q3 2020, up 137%, Adjusted EBITDA1: $32.2 million in Q3 2021, as compared to $7.8 million in Q3 2020, up 312%.

VP WATCHLIST HIGHLIGHTS

Our complete VP Watchlist is a list that we believe deserves consideration for short term and long term portfolio adds that include Apple, Tesla, Disney & 8 other names currently. The dedicated pages for each of these companies will enable you to stay informed and learn more about these companies daily. Please review few of the updates on a few of the VP Watchlist companies below:


  • Shares of VP Watchlist stock INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $19.53, +.72%, after reaching an intraday high of $20.
    • Today after the close, INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported its financial results for the third quarter ended September 30, 2021 and provided a business update including the announcing of a second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) & Cash and cash equivalents of $84.5 million on September 30th. RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “In the first patient treated in our Phase I study of INKmune™ in high-risk myelodysplastic syndrome, INKmune™ was found to safely produce cancer killing memory-like NK cells while increasing proliferation and persistence of those NK cells. As expected, the memory-like NK cells generated in vivo killed NK-resistant cancer cells in vitro. We now have data from Day 73 post first treatment and over 60% of his peripheral blood NK cells remained activated and highly functional in vitro. We are continuing to screen patients for future enrollment and are in the process of expanding the number of clinical trial sites in the UK and overseas. Our latest drug stability data allows us to extend the shelf-life to over 12 months and consequently we initiated a manufacturing scale up to secure drug supplies as the program expands. In our Phase I trial of XPro in AD, we have shown that XPro decreases biomarkers of neuroinflammation and neurodegeneration while improving biomarkers of CNS repair. We hope to demonstrate these effects on cognition in the Phase II mild AD trial that is on track to initiate later this year.” INmune Bio announced that they will deliver multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that is being held during November 9-12 in Boston. For details please visit the following link. 
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management today, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.
    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
 

  • Shares of Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, closed at $60.38/share, +4.36%. The 52-wk high is $121.16. 
    • Fate will host a conference call and live audio webcast on Thursday, November 4, 2021 at 5:00 p.m. ET to report its third quarter 2021 financial results and provide a corporate update.In order to participate in the conference call, please dial (877) 303-6235 (domestic) or (631) 291-4837 (international) and refer to conference ID 9459084. The live webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.



  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.37.
    • On October 20, INVO Bioscience, Inc. announced that four exciting poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland. “It’s extremely rewarding to see our technology highlighted at this year’s ASRM. Four independent abstracts were selected for presentation at the fertility industry’s most prominent annual meeting. On behalf of the entire INVO team, we sincerely appreciate the work of the many clinicians that now support INVOcell as a solution and thank those that contributed their independent work in advancing the understanding of the unique capabilities of INVOcell. These types of events and studies emphasize the opportunity we have to democratize advanced fertility services through the unique attributes of the INVOcell solution and bring care to the large, underserved patient population around the world,” stated Steve Shum, CEO of INVO Bioscience. LEARN MORE! 
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions.
          • The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
          • Also, on Oct. 1, INVO entered into a separate Stock Purchase Agreement with Paradigm Opportunities Fund, LP an accredited institutional investor, pursuant to which we will issue to such investor 600,703 shares of their common stock, par value $0.0001 per share for a purchase price of $3.329 per share for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. The Shares will be issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended. The Purchase Agreement contains a $250,000 break-up fee whereby if either party fails to close, it will be required to pay the non-breaching party a fee of $250,000. The investor under the Purchase Agreement also agreed to a 1-year lock up period with respect to the Shares.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, was officially opening on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”
    • Over the past 40+ years, since the first IVF baby was born, the fertility market has grown into a $20+ billion global industry. Here in the U.S., according to the most recent 2019 CDC data, approximately 330,000 IVF cycles were performed across 448 clinics, which implies a roughly $5 billion domestic marketplace. However, this represents only a small portion of the actual market as approximately 90% of infertile couples go untreated each year. There are some real challenges with bridging the gap of treating the volume of patients that need care. Patient affordability and lack of insurance coverage is often the most discussed dynamic, but that is only one part of the challenge. We believe that there is an equal or even greater challenge related to capacity limitations in the industry given the relatively small number of IVF clinics and limited human resources available which are typically only available in major metropolitan areas. We believe that INVO Biosceince’s INVOcell, without the need of expensive lab build outs, can bring much needed capacity additions and access to the market beyond the major metropolitan areas at a more affordable price.


  • Shares of VP Watchlist firm, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $2.84, +2.16% on +2.82M shares of trading volume after reaching a high of $2.81 in intraday trading. 
    • On October 21, Atossa Therapeutics, Inc. (Nasdaq: ATOS) released a short video message recognizing Breast Cancer Awareness Month, and urging women to get mammograms. In the video message, which can be found on Atossa’s website here, Dr. Quay cites that the global pandemic “changed everything” with regard to breast cancer screening, indicating that many women have ceased to seek out their mammograms since the initial COVID-19 outbreak. This is corroborated in an article in the October 2021 issue of the peer-reviewed medical journal, Preventative Medicine, which indicated this was a particular problem in women of color and those who fall in the lower income brackets.
    • On September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.


  • Shares of VP Watchlist stock, InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed trading at $1.54, +1.99%.  The 52-wk range is $1.38 – $8.94. 
    • On October 13, InMed announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.”
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”

    • I hosted the INM management team on the Tribe Public Network on Tuesday, September 21 for a 30-minute FREE Presentation and Q&A Webinar Event. Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) & Shane Johnson, MD, Co-Founder of BayMedica delievered a presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” They held a Q&A session at the end of the presentation. You may view the video of the event at the Tribe Public YouTube Channel here.
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with a BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price target.
    • On Aug.9th, I published an informative story titled “A Recent Discussion With The CEO of InMed Pharmaceuticals (NASDAQ: INM) Regarding Development Of IntegraSyn™, A Proprietary Manufacturing Approach To Economically Produce Pharmaceutical-Grade Cannabinoids” PLEASE READ NOW.
    • On July 2nd, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.

Economic Reports

  • On Monday & Tuesday, no reports were released.   
  • On Wednesday, the Fed’s decision to keep interest rates near zero surfaced, while they also committed to taper net asset purchases by $15B this month; moves that were somewhat expected.  The Fed also reemphasized that in order for rates to be raised, we would need to reach maximum employment, They also restated that inflation pressures are truly transitory at best. The ISM Non-Manufacturing Index report for October confirmed a rise to 66.7%, while the factory orders for manufactured goods report confirmed a rise by .2% M/M in September. The ADP Employment Change report approximated that 571k jobs were added to private-sector payrolls in October. The IHS Markit Services PMI report confirmed a rise to 58.7 in the final reading for October. The weekly MBA Mortgage Applications Index report confirmed drop by 3.3%. The weekly crude oil inventories was confirmed to have risen by 3.29M barrels (a rise for a second consecutive weeks), while oil prices fell 3.6% to close at $80.81/bbl.

Investing & Inspiration

  1. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  2. “If opportunity doesn’t knock, build a door.” – Milton Berle
  3. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  4. “The smallest deed is better than the greatest intention.” – John Burroughs
  5. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  6. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  7. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  8. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  9. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  10. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  11. “Don’t go through life, grow through life.”– Eric Butterworth
  12. “This life is worth living, we can say, since it is what we make it.” – William James
  13. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  14. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  15. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  16. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  17. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  18. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  19. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  20. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  21. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  22. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  23. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden

  24. “One fails forward toward success.” – Charles Kettering

  25. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  26. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  27. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  28. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  29. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  30. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  31. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  32. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  33. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  34. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  35. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  36. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  37. “It takes a long time to grow an old friend.” – John Leonard
  38. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  39. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  40. “Man is only great when he acts from passion.” – Benjamin Disraeli
  41. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  42. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  43. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  44. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  45. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  46. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  47. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  48. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  49. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  50. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  51. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  52. “Every good painter paints what he is.” – Jackson Pollock
  53. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  54. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  55. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  56. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  57. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  58. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  59. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  60. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  61. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  62. “Eliminate emotion from your investment program.” -John C. Bogle

  63. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  64. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  65. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  66. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  67. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  68. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  69. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  70. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  71. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  72. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  73.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  74. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  75. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  76. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  77. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  78. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  79. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  80. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  81. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  82. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  83. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  84. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  85. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  86. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  87. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  88. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  89. “View health as an investment, not an expense.” – John Quelch

  90. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  91. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  92. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  93. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  94. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  95. “A problem is a chance for you to do your best.”–  Duke Ellington
  96. “The best way to predict the future is to create it.” -Peter Drucker
  97. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  98. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  99. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  100. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  101. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  102. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  103. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  104. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  105. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  106. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  107. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  108. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  109. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  110. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  111. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  112. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  113. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  114. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  115. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  116. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  117. “Modern medical advances have helped millions of people live longer, healthier lives.

  118. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  119. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  120. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  121. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  122. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  123. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  124. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  125. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  126. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  127. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  128. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  129. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  130. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  131. “Investment is most successful when it is most businesslike.” – Ben Graham

  132. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  133. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  134. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  135. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  136. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  137. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  138. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  139. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  140. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  141. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  142. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  143. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  144. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  145. “Know what you own, and know why you own it.” – Peter Lynch
  146. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  147. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  148. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  149. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  150. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  151. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  152. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  153. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  154. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  155. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  156. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  157. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  158. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  159. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  160. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  161. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  162. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  163. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  164. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  165. “No Price is too low for a bear or too high for a bull.” — Anonymous
  166. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  167. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  168. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  169. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  170. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  171. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  172. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  173. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  174. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  175. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  176. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  177. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  178. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  179. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  180. “Know what you own, and know why you own it.” – Peter Lynch
  181. “Liquidity is only there when you don’t need it.” -Old Proverb
  182. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  183. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  184. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  185. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  186. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  187. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  188. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  189. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  190. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  191. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  192. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  193. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  194. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  195. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  196. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  197. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  198. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  199. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  200. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  201. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  202. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  203. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: